María Luz Muzzio

Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome

Metalloproteinases (MMPs) play a significant role in vascular remodeling, and they have been suspected to be partly responsible for the pathogenesis of cardiovascular disease. Metalloproteinases have been reported to be increased in atherosclerosis and type 2 diabetes mellitus; however, so far they have not been evaluated in metabolic syndrome (MetS). Plasma activity of MMP-2 and MMP-9, high-sensitivity C-reactive protein concentration, dense low-density lipoprotein, and insulin-resistance markers were measured in 38 nondiabetic women with (n = 19) and without (n = 19) MetS. Women with MetS had significantly higher plasma activity of MMP-2 than controls (median [range], 1.3 [0.4-3.1] vs 0.7 [0.1-1.9]; P = .001). MMP-2 activity positively correlated with waist, homeostasis model assessment, and high-sensitivity C-reactive protein (P < .02) as well as with apolipoprotein B, dense low-density lipoprotein, triglycerides/high-density lipoprotein cholesterol index (P < .001) and negatively with high-density lipoprotein cholesterol (P < .002). Our finding of increased plasma activity of MMP-2 in women with MetS is important because they fit in with an early stage of cardiovascular disease; and measurement of soluble molecules may improve the risk assessment, early diagnosis, and prognosis of cardiovascular disease.

Metalloproteases 2 and 9, Lp-PLA2 and Lipoprotein Profile in Coronary Patients

BACKGROUND AND AIMS Many studies suggest that the different steps of the atherosclerotic process may be mediated by metalloproteases (MMPs). MMP-9 and MMP-2, which are highly expressed in the vulnerable regions of the atherosclerotic plaques, have been suggested to be causally involved in plaque rupture. In another manner linked with LDL, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) hydrolyzes phospholipids generating proinflammatory and proatherogenic products. Our aim was to evaluate plasma activity of MMP-2 and 9, as well as Lp-PLA(2), in subjects with coronary artery stenosis in comparison with controls and to correlate these activities with lipoprotein profile and general biomarkers of inflammation. METHODS Forty two subjects who had undergone coronary angiography were divided into two groups: patients with coronary vessels with at least 45% stenosis (CAD [coronary artery disease], n = 24) and patients without angiographically detectable coronary artery disease (controls, n = 18). Plasma activity of MMP-2 and MMP-9 was measured and correlated with markers of systemic inflammation (hs-CRP), subendothelial inflammation (Lp-PLA(2)) and lipoprotein profile. RESULTS Plasma activity of both MMPs was consistently higher in patients than in controls (p <0.01). Pro-MMP-2 (r = 0.34, p <0.01) and MMP-9 (r = 0.51, p <0.02) activities correlated with apoprotein B. Pro-MMP-2 correlated with hs-CRP (r = 0.47, p <0.01) and inversely with HDL cholesterol (r = -0.35, p <0.02). No differences were observed in Lp-PLA(2) between patients and controls (15.2 +/- 4.0 vs. 15.4 +/- 4.5 micromol/mL/h, p = NS, respectively), and no correlation was observed with MMPs. CONCLUSIONS MMP activity was higher in CAD than in controls. The correlation observed between pro-MMP-2 and high-sensitive C-reactive protein (hs-CRP) may be due to specific systemic inflammatory processes. No correlation was observed between Lp-PLA(2) and MMPs.

A new approach to the quantitative measurement of dense LDL subfractions

OBJECTIVES Small dense low-density lipoproteins (LDLs) should be considered a major risk factor for cardiovascular disease, but there is still no recommended method for measuring them or expressing clinical values. We measured the dense LDL portion relatively simply by isolating it using density ultracentrifugation and then giving it a relative, quantitative value. DESIGN AND METHODS Dense LDLs (d=1.048-1.063 g/mL) were isolated from human plasma at the same time as total LDL (d=1.021-1.063 g/mL) by means of sequential ultracentrifugation, and the former was assessed as a percentage of the latter. A receiver operator characteristic (ROC) curve was used to compare the different LDL components as markers of dense LDLs. The proposed method was compared with non-denaturing gradient gel electrophoresis (NDGGE). In order to obtain clinical data, the dense LDL portion was measured in diabetic and postmenopausal subjects and healthy controls. RESULTS The ROC curve showed that cholesterol level was a more accurate marker of dense LDLs. The within-run precision (CV) was 2.28%, and the between-run CV was 5.1%. Analytical recovery was 80.2+/-1.6%. The correlation between the proposed method and NDGGE was r=0.90, p<0.001. The dense LDL percentage significantly correlated with serum triglyceride (r=0.57, p<0.001) and high-density lipoprotein cholesterol levels (r=-0.33, p<0.01), but not with the LDL-cholesterol/apolipoprotein B ratio. The diabetic patients and postmenopausal women had higher dense LDL values than the healthy controls. CONCLUSIONS The results obtained using this procedure are in line with those obtained using NDGGE, which is the conventional assay system for measuring LDL size. Determining the small dense LDL portion by means of its cholesterol content may be a better approach to characterising the risk of cardiovascular disease, even in the presence of relatively normal LDL-cholesterol levels.

Increased MMP-2 in healthy postmenopausal women

Background Matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) are involved in the atherosclerosis process. The objective of the study was to evaluate MMP-2 and MMP-9 activities and other circulating inflammatory factors in healthy postmenopausal women (PMW) as a model of subclinical atherosclerosis. Methods Twenty-three PMW and 13 premenopausal women (PreMW) were selected following established criteria. The main measurements in plasma samples were: lipid–lipoprotein profile, high-sensitivity C-reactive protein (hs-CRP) (immunoturbidimetry), soluble vascular cellular adhesion molecules (sVCAM-1) enzyme-linked immunosorbent assay and MMP activity by zymography. Results The relative areas of MMP-2 were increased in PMW: 1.1 (0.1) versus 0.6 (0.05), P < 0.02. MMP-9 was only detected in three PMW and one PreMW. MMP-2 correlated with HDL-cholesterol (r = −0.51), triglycerides (r = 0.67), apolipoprotein B (r = 0.47), hs-CRP (r = 0.42), homeostasis model assessment (r = 0.53) and waist circumference (r = 0.40), at least P < 0.02. sVCAM-1 showed no difference between groups: 28.7 (5.5) versus 35.5 (20) ng/mL, but correlated with MMP-2 and hs-CRP (r = 0.46 and r = 0.48 respectively, P < 0.05). Conclusions In postmenopause, the increase in MMP-2 reflects the systemic specific inflammatory process that accompanies atherogenesis.